Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application

Inclusion Criteria: * Healthy female volunteers * Age between 18-38 years * Body mass index 17-29 kg/m2 * Woman of child bearing potential must agree to practice effective barrier methods for birth control * Use of oral contraceptives for at least 3 months before study entry * Regular menstruation cycle (25-34 days) before initiation of oral contraception * Presence of both ovaries * Normal findings in medical history and physical and gynaecological examination unless the investigator considers an abnormality to be clinically irrelevant for this study * Signed informed consent Exclusion Criteria: * Polycystic ovary syndrome (PCOS) * History of hypersensitivity to FSH (Ovary Hyperstimulation Syndrome, OHSS) * Impaired thyroid function (treated or untreated) * History of malignant disease * AST and/or ALAT \> 2 x ULN * Other clinically relevant findings (ECG, blood pressure, physical, gynecological examination, laboratory examination) * Smoking habits of more than 5 cigarettes per day * Abuse of alcoholic beverages and drugs * Participation in a clinical trial within 3 weeks prior to the study * Foreseen inability to attend to scheduled study visits * Symptoms of a clinically relevant illness during 3 weeks prior the first study day * Pregnancy or lactation period * Any medical condition that, in the opinion of the investigator, would interfere with safety of the subject or interference of the objectives of the study